KMPH KemPharm Inc.

0.98
-0.03  -3%
Previous Close 1.01
Open 1.01
Price To Book -0.36
Market Cap 29,160,396
Shares 29,758,543
Volume 135,073
Short Ratio
Av. Daily Volume 145,190

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due by the end of 2019.
KP415
ADHD
CRL issued June 13, 2016. Resubmitted, and issued FDA Approval February 23, 2018.
Apadaz (KP201/APAP)
Acute pain
NDA filing planned for 2020.
KP484
ADHD

Latest News

  1. KemPharm Reports Second Quarter 2019 Results
  2. Implied Volatility Surging for KemPharm (KMPH) Stock Options
  3. Could The KemPharm, Inc. (NASDAQ:KMPH) Ownership Structure Tell Us Something Useful?
  4. KemPharm Reports First Quarter 2019 Results
  5. KemPharm Completes KP415 Pre-NDA Meeting with FDA
  6. Edited Transcript of KMPH earnings conference call or presentation 28-Feb-19 9:30pm GMT
  7. KemPharm Provides Update on APADAZ® Formulary Adoption
  8. Loss-Making KemPharm, Inc. (NASDAQ:KMPH) Expected To Breakeven
  9. KemPharm to Present at Upcoming Investor Conferences
  10. KemPharm Reports Q4 and FY 2018 Results
  11. KemPharm, Inc. to Host Earnings Call
  12. KemPharm to Report Fourth Quarter and Year End 2018 Results
  13. KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate
  14. What You Must Know About KemPharm, Inc.’s (NASDAQ:KMPH) Beta Value
  15. KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting
  16. KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)
  17. New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiatives and Sustained Production
  18. KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio
  19. KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
  20. KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing